(Q38005994)

26 August 2017

title

Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management (English)

1 reference

26 August 2017

I Manousaridis

1

1 reference

26 August 2017

S Mavridou

2

1 reference

26 August 2017

S Goerdt

3

1 reference

26 August 2017

M Leverkus

4

1 reference

26 August 2017

J Utikal

5

1 reference

26 August 2017

publication date

28 April 2012

1 reference

Journal of the European Academy of Dermatology and Venereology

26 August 2017

published in

1 reference

26 August 2017

volume

27

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

11-18

1 reference

Mutations of the BRAF gene in human cancer

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

B-RAF is a therapeutic target in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Targeting BRAF for patients with melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Ras/Erk MAPK signaling in epidermal homeostasis and neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Ras oncogenes: split personalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Essential role of B-Raf in ERK activation during extraembryonic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

A role for the mitogen-activated protein kinase kinase kinase 1 in epithelial wound healing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

VDR and MEK-ERK dependent induction of the antimicrobial peptide cathelicidin in keratinocytes by lithocholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

RAF inhibition and induction of cutaneous squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Management of the Cutaneous Side Effects of Therapeutic Epidermal Growth Factor Receptor Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Opposing roles for calcineurin and ATF3 in squamous skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Cutaneous reactions related to systemic immunomodulators and targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

Erratum: Ras and Raf pathways in epidermis development and carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04546.X

10.1111/J.1468-3083.2012.04546.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference